Developing 68 Ga-Labeled Exendin(9–39) Derivatives for PET Imaging of Insulinomas
Bioconjugate Chemistry · 2025
DOI: 10.1021/acs.bioconjchem.5c00513 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Tuo Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, State Key Laboratory of Common Mechanism Research for Major Diseases, Chinese Academy of Medical Sciences and Peking …. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Gallium Radioisotopes, Insulinoma, Pancreatic Neoplasms. Die Arbeit nennt 21 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Peking Union Medical College Hospital, National Natural Science Foundation of China.
Abstract (Originalsprache)
Glucagon-like peptide-1 receptor (GLP-1R) is overexpressed in >90% of insulinomas, making it an optimal target for imaging. However, current GLP-1R agonist tracers may induce side effects including hypoglycemia and nausea, particularly in pediatric patients. In this study, we employed a rational design approach combining molecular dynamics (MD) simulations with experimental validation to develop three 68Ga-labeled NOTA-conjugated exendin(9-39) derivatives featuring antagonist activity for safer imaging. MD simulations predicted differential binding affinities based on conjugation sites at Asp09 (E09), Lys12 (E12), and Lys27 (E27), with MM/GBSA calculations ranking E09 (-216.06 kcal/mol) > E12 (-200.01 kcal/mol) > E27 (-117.08 kcal/mol). Experimental validation through surface plasmon resonance confirmed these computational predictions, showing binding affinities consistent with the computational predictions. All radiotracers achieved radiochemical yields (>95%) and plasma stability (>91% intact after 120 min). In vivo PET imaging validated the computational hierarchy, with [68Ga]Ga-E09 demonstrating superior tumor uptake (SUVmax: 3.99 at 60 min) compared with E12 (SUVmax: 0.75 at 60 min) or E27 (undetectable). These findings highlight the power of combining computational screening with systematic experimental validation. In conclusion, [68Ga]Ga-E09 demonstrates superior binding affinity, cellular uptake, and imaging performance, suggesting its potential as a promising agent warranting further studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, State Key Laboratory of Common Mechanism Research for Major Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital, Beijing 100730, China.
ORCID-Profile: Tuo Li
Förderung
- National Key Research and Development Program of China
- Peking Union Medical College Hospital
- National Natural Science Foundation of China
- National High Level Hospital Clinical Research Funding
Zitieren
APA
Li, T., Li, L., & Luo, Y. (2025). Developing 68 Ga-Labeled Exendin(9–39) Derivatives for PET Imaging of Insulinomas. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00513
Vancouver
Li T, Li L, Luo Y. Developing 68 Ga-Labeled Exendin(9–39) Derivatives for PET Imaging of Insulinomas. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00513
BibTeX
@article{Li2025,
author = {Li, Tuo and Li, Linlin and Luo, Yaping},
title = {Developing 68 Ga-Labeled Exendin(9–39) Derivatives for PET Imaging of Insulinomas},
journal = {Bioconjugate Chemistry},
year = {2025},
doi = {10.1021/acs.bioconjchem.5c00513}
}
EUVIMED